Moxifloxacin-Induced Immune-Mediated Thrombocytopenia in a Chronic Kidney Disease Patient Receiving Hemodialysis
| Autor: | Dan Martinusen, Caroline Stigant, Jonathan Mailman |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease Thrombocytopenic purpura Dyscrasia Surgery Moxifloxacin Internal medicine medicine Pharmacology (medical) Hemodialysis Complication Adverse effect business Dialysis Kidney disease medicine.drug |
| Zdroj: | The Annals of pharmacotherapy. 48(7) |
| ISSN: | 1542-6270 |
| Popis: | Objective:To alert clinicians to a serious complication from a commonly prescribed medication, moxifloxacin. Case Summary: A 65-year-old male, septic, hemodialysis patient developed thrombocytopenia following exposure to vancomycin, ceftazidime, and moxifloxacin. Drug-specific immunoglobulin testing showed positive autoantibodies against only moxifloxacin, and the probability stratification proposed by Naranjo et al would give this case a score of 7—a probable association between moxifloxacin and the adverse event. Discussion: Idiopathic thrombocytopenic purpura (ITP) results in immune-mediated platelet destruction, with bleeding risk frequently manifested by purpuric skin and mucosal lesions. Although many drugs are associated with ITP, moxifloxacin has only been characterized in 2 previous case reports. This is the first case report where specific immunoglobulin antibody testing showed a positive association between ITP and moxifloxacin. Conclusions: Moxifloxacin is a commonly prescribed medication because of its wide spectrum of activity, high bioavailability, and convenient dose schedule. Clinicians need to be aware of this little-known side effect of this commonly prescribed antibiotic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|